A triple-agonist just posted 30% weight loss at two years. Surgical-magnitude, from a once-weekly shot.
And I'm convinced it's the least important thing that happened to obesity medicine this year. Here's why the biggest number stopped being the story. 🧵
1/ For three years, we ranked these drugs like a leaderboard:
Semaglutide: ~15%.
Tirzepatide: ~21%.
Then retatrutide crossed 28%.
Every year, a bigger number.
We got very good at asking one question: how much weight comes off? That's now the wrong question.
2/ What actually changed in 2026: the class now pulls four different levers.
🔹GLP-1: eat less, ⬇️ inflammation, ⬇️ glucose
🔹GIP: tolerate more, sharpen insulin response
🔹Glucagon: burn more, clear liver fat
🔹Amylin: eat less through a separate circuit, ⬆️ leptin sensitivity
3/ Retatrutide's pivotal trial, TRIUMPH-1: 28.3% at 80 weeks, up to 30.3% at two years in severe obesity. 45% of patients crossed 30% loss.
That's the glucagon lever partly at work. It doesn't just quiet appetite. It tells the body to burn.
4/ But the most important approval of the year wasn't the strongest drug. It was a pill.
Orforglipron: the first non-peptide oral GLP-1. Only ~11-12% weight loss. No needle, no fasting, no cold chain.
It's not competing on the leaderboard. It's competing on the front door.
5/ Then the twist most clinicians are underrating: the liver.
Glucagon drugs treat steatohepatitis directly. Survodutide improved MASH in 62% of patients vs 14% on placebo.
These are starting to look like liver drugs that happen to cause weight loss.
6/ Not every bet paid off. CagriSema, the big amylin combo, lost a head-to-head to tirzepatide: 23% vs 25.5%.
Stacking pathways doesn't automatically win.
So the job quietly changed: from "prescribe the strongest" to "match the mechanism to the patient."
7/ The patient who needs 10% to reverse prediabetes and the one who needs 25% to get off CPAP no longer get the same prescription. They never should have. The best news in obesity medicine is that it finally got complicated: substance-over-noise.beehiiv.com/p/obesity-medi…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.